Prothena (STU:0PT) Valuation Rank


STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €8.61
GF Value €12.84
! 2 Warning Signs
View Full Analysis

What is Prothena Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Prothena Valuation Rank Related Terms

STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €8.61 is trading 32.9% below its estimated GF Value™ of €12.84.

Key valuation signals for STU:0PT:

  • Valuation Rank:
  • GF Value™: €12.84 vs. price of €8.61 (32.9% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.61
Price
€12.84
GF Value